Sign In
Buy ATRC
$26.20
+0.340 (+1.31%)
At Close: Jun 03, 2026
Insider Selling: AtriCure Inc. (NASDAQ:ATRC) SVP Sells $350,000.00 in Stock
08:56am, Sunday, 12'th Apr 2020
AtriCure Inc. (NASDAQ:ATRC) SVP Justin J. Noznesky sold 10,000 shares of the company’s stock in a transaction on Tuesday, April 7th. The stock was sold at an average price of $35.00, for a total tra
AtriCure Inc. (NASDAQ:ATRC) Shares Bought by Bank of America Corp DE
10:46am, Saturday, 11'th Apr 2020
Bank of America Corp DE lifted its position in AtriCure Inc. (NASDAQ:ATRC) by 1.9% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. T
Mark A. Collar Sells 4,000 Shares of AtriCure Inc. (NASDAQ:ATRC) Stock
10:02am, Saturday, 11'th Apr 2020
AtriCure Inc. (NASDAQ:ATRC) Director Mark A. Collar sold 4,000 shares of the company’s stock in a transaction dated Tuesday, April 7th. The stock was sold at an average price of $36.07, for a total
AtriCure Inc. (NASDAQ:ATRC) Shares Purchased by Bank of New York Mellon Corp
09:14am, Saturday, 11'th Apr 2020
Bank of New York Mellon Corp boosted its stake in AtriCure Inc. (NASDAQ:ATRC) by 2.8% during the fourth quarter, Holdings Channel.com reports. The fund owned 322,206 shares of the medical device compa
Q1 2020 Earnings Estimate for AtriCure Inc. Issued By Oppenheimer (NASDAQ:ATRC)
05:34am, Friday, 10'th Apr 2020
AtriCure Inc. (NASDAQ:ATRC) – Stock analysts at Oppenheimer issued their Q1 2020 earnings per share estimates for AtriCure in a report released on Monday, April 6th. Oppenheimer analyst S. Kalia for
Atricure (ATRC) Received its Third Buy in a Row
06:49pm, Thursday, 09'th Apr 2020
After Needham and Piper Sandler gave Atricure (NASDAQ: ATRC) a Buy rating last month, the company received another Buy, this time from Oppenheimer.
Atricure (ATRC) Received its Third Buy in a Row
06:49pm, Thursday, 09'th Apr 2020
After Needham and Piper Sandler gave Atricure (NASDAQ:
ATRC
) a Buy rating last month, the company received another Buy, this time from Oppenheimer. Analyst
Suraj Kalia
maintained a
Buy
rating on Atri
AtriCure C-suite taking pay cuts as revenue dips because of coronavirus
04:26pm, Thursday, 09'th Apr 2020
Mike Carrel is CEO of AtriCure.
Atricure (ATRC) Gets a Buy Rating from Needham
02:33pm, Thursday, 09'th Apr 2020
In a report released today, Michael Matson from Needham maintained a Buy rating on Atricure (ATRC), with a price target of $49.00. The company's shares
Atricure (ATRC) Receives a Buy from BTIG
01:34pm, Thursday, 09'th Apr 2020
BTIG analyst Marie Thibault maintained a Buy rating on Atricure (ATRC) today and set a price target of $45.00. The company's shares closed last Thursday
Atricure (ATRC) Receives a Buy from BTIG
01:34pm, Thursday, 09'th Apr 2020
BTIG analyst Marie Thibault maintained a Buy rating on Atricure (ATRC – Research Report) today and set a price target
AtriCure announces actions in response to COVID-19 pandemic ATRC
12:31pm, Thursday, 09'th Apr 2020
AtriCure announces actions in response to COVID-19 pandemic ATRC
AtriCure reports preliminary Q1 revenue $53.2M, consensus $59.84M ATRC
12:30pm, Thursday, 09'th Apr 2020
AtriCure reports preliminary Q1 revenue $53.2M, consensus $59.84M ATRC
AtriCure Announces Preliminary Financial Results for First Quarter 2020 and Provides COVID-19 Pandemic Update
12:00pm, Thursday, 09'th Apr 2020
AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced preliminary financial results for the first
